Patients who were admitted to West China Hospital from June 2012 to June 2019 and diagnosed with
anti-NMDAR encephalitis were enrolled in the study. Medical records were reviewed prospectively to gather clinical characteristic data. Patients were followed up at long-term every 3 months.
Results: This study included 192 patients, among whom 21 (10.9%) were detected with having a
teratoma. Patients included 20 women, with a mean age of 24.62 ± 7.61 years. Seizure and psychiatric symptoms were the most dominant symptoms in both groups, followed by
memory deficits. Central
hypoventilation (52.4 vs. 17%, p < 0.001) and decreased consciousness (71.4 vs. 31.3%, p = 0.002) were significantly more frequent in patients with
teratoma than in those without. Moreover, the anti-NMDAR antibody titer was higher (p = 0.021) and the baseline modified Rankin scale score was lower (p = 0.004) in patients with
teratoma than in those without. First-line
immunotherapy was performed in 21 (100%) patients with
teratoma and 167 (97.7%) patients without
teratoma. All patients with
teratoma had the
tumor removed. During follow-up, two (9.5%) patients with
teratoma and 11 (6.4%) patients without
teratoma died, whereas 1 (4.8%) patient with
teratoma and 37 (21.6%) patients without
teratoma had relapses. Overall, 19 (90.5%) patients with
teratoma and 151 (88.3%) patients without
teratoma achieved favorable clinical outcomes at the final follow-up.
Conclusions: